LIT

MEI Pharma (LITS) Q3 2024 Earnings

LITS·Reported September 30, 2024

Diluted EPS came in at $-1.20, beat the $-1.70 consensus by $0.50.

Diluted EPS
$-1.20beat by $0.50
Consensus: $-1.70
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-24-125328

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about MEI Pharma's Q3 2024 earnings report.

MEI Pharma (LITS) reported Q3 2024 earnings on September 30, 2024.

MEI Pharma reported diluted EPS of $-1.20 for Q3 2024.

EPS beat the consensus estimate of $-1.70 by $0.50.

You can read the 10-Q periodic report (0000950170-24-125328) directly on SEC EDGAR. The filing index links above go to sec.gov.